Category
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Today's News
More News
Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma

Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma

Administration of the PD-L1 inhibitor camrelizumab combined with the selective multikinase inhibitor famitinib elicited responses and was well tolerated in patients with advanced acral or mucosal mela

Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma

Administration of the PD-L1 inhibitor camrelizumab combined with the selective multikinase inhibitor famitinib elicited responses and was well tolerated in patients with advanced acral or mucosal mela
Gene Therapy Study Identifies Potential New Treatment for Liver Cancer

Gene Therapy Study Identifies Potential New Treatment for Liver Cancer

Gene therapy that induces the body to create microRNA-22 (miR-22), a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma, the most common form of liver cancer.The miR

Gene Therapy Study Identifies Potential New Treatment for Liver Cancer

Gene therapy that induces the body to create microRNA-22 (miR-22), a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma, the most common form of liver cancer.The miR
Hackensack Meridian JFK University Medical Center Thoracic Surgeons Perform the First Robotic Resection Surgery for Malignant Thymoma with Intraoperative Installation of Heated Chemotherapy

Hackensack Meridian JFK University Medical Center Thoracic Surgeons Perform the First Robotic Resection Surgery for Malignant Thymoma with Intraoperative Installation of Heated Chemotherapy

Surgeons affiliated with Hackensack Meridian JFK University Medical Center’s Advanced Lung and Airway Center successfully performed the first robotic resection of malignant thymoma, a cancer of the th

Hackensack Meridian JFK University Medical Center Thoracic Surgeons Perform the First Robotic Resection Surgery for Malignant Thymoma with Intraoperative Installation of Heated Chemotherapy

Surgeons affiliated with Hackensack Meridian JFK University Medical Center’s Advanced Lung and Airway Center successfully performed the first robotic resection of malignant thymoma, a cancer of the th
Cancer patients and oncologists support complementary therapies, but communication gap exists

Cancer patients and oncologists support complementary therapies, but communication gap exists

Patients and oncologists are supportive of complementary therapies, such as nutrition counseling, exercise, massage, and mediation, for cancer treatment, according to a new survey conducted on behalf

Cancer patients and oncologists support complementary therapies, but communication gap exists

Patients and oncologists are supportive of complementary therapies, such as nutrition counseling, exercise, massage, and mediation, for cancer treatment, according to a new survey conducted on behalf
Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer

Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer

Treatment with intra-arterial (IA) gemcitabine led to an improvement in overall survival (OS) compared with continued treatment with intravenous (IV) gemcitabine plus nab-paclitaxel (Abraxane) in pati

Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer

Treatment with intra-arterial (IA) gemcitabine led to an improvement in overall survival (OS) compared with continued treatment with intravenous (IV) gemcitabine plus nab-paclitaxel (Abraxane) in pati
Clinic-based community program shows promise in addressing food insecurity and improving health

Clinic-based community program shows promise in addressing food insecurity and improving health

The FISH (Food Insecurity and its Sequalae on Health) Study, led by Tiffany Wesley Ardoin, MD, FACP, Assistant Professor of Clinical Medicine at LSU Health New Orleans' Baton Rouge Regional Campus

Clinic-based community program shows promise in addressing food insecurity and improving health

The FISH (Food Insecurity and its Sequalae on Health) Study, led by Tiffany Wesley Ardoin, MD, FACP, Assistant Professor of Clinical Medicine at LSU Health New Orleans' Baton Rouge Regional Campus
Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Low-Grade Serous Ovarian Cancer

Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Low-Grade Serous Ovarian Cancer

The RAF/MEK and FAK inhibitor combination avutometinib (VS-6766) plus defactinib (VS-6063) represents a novel area of exploration that has displayed clinical activity and a manageable safety profile i

Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Low-Grade Serous Ovarian Cancer

The RAF/MEK and FAK inhibitor combination avutometinib (VS-6766) plus defactinib (VS-6063) represents a novel area of exploration that has displayed clinical activity and a manageable safety profile i
TNB-486 Elicits 91% CR Rate in Heavily Pretreated, High-Risk Follicular Lymphoma

TNB-486 Elicits 91% CR Rate in Heavily Pretreated, High-Risk Follicular Lymphoma

TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy, according t

TNB-486 Elicits 91% CR Rate in Heavily Pretreated, High-Risk Follicular Lymphoma

TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy, according t
AI-based method shows promise for precision medicine

AI-based method shows promise for precision medicine

Artificial intelligence, AI, which finds patterns in complex biological data could eventually contribute to the development of individually tailored healthcare. Researchers at Linköping University in

AI-based method shows promise for precision medicine

Artificial intelligence, AI, which finds patterns in complex biological data could eventually contribute to the development of individually tailored healthcare. Researchers at Linköping University in
SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

The second line may be the optimal setting for patients with HR-positive, HER2-negative advanced breast cancer to receive CDK4/6 inhibitors, according to findings from the phase 3 SONIA trial (NCT0342

SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

The second line may be the optimal setting for patients with HR-positive, HER2-negative advanced breast cancer to receive CDK4/6 inhibitors, according to findings from the phase 3 SONIA trial (NCT0342
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...